7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 
      
    		                               
      cash flow from operating activities
    		                               
      net income
    		-135,000,000 0 -112,000,000 -94,000,000 -92,000,000 -93,000,000 -4,000,000 -81,000,000 -71,000,000 -75,000,000 -80,000,000 -67,456,000 -64,919,000 -66,632,000 -67,993,000 279,368,000 -77,975,000 -75,970,000 -72,593,000 -51,853,000 1,822,000 -45,074,000 -27,753,000 -16,598,000 -22,352,000 -28,090,000 -17,670,000 -12,295,000 -10,811,000 -13,534,000 -12,954,000 
      adjustments to reconcile net income to net cash from operating activities:
    		                               
      stock-based compensation expense
    		14,000,000 15,000,000 16,000,000 17,000,000 19,000,000 20,000,000 20,000,000 18,000,000 18,000,000 18,000,000 19,000,000 16,522,000 16,260,000 15,677,000 16,541,000 13,815,000 14,585,000 13,367,000 12,761,000 7,891,000 6,002,000 4,470,000 3,462,000 2,437,000 2,740,000 2,130,000 1,674,000 1,054,000 1,048,000 1,116,000 656,000 
      depreciation and amortization
    		2,000,000 2,000,000 3,000,000 3,000,000 2,000,000 2,000,000 3,000,000 3,000,000 1,000,000 2,000,000 2,000,000 1,478,000 1,560,000 1,505,000 1,457,000 1,260,000 963,000 820,000 800,000 778,000 742,000 787,000 842,000 856,000 886,000 883,000 953,000 947,000 974,000 915,000 828,000 
      noncash lease expense
    		2,000,000 1,000,000 2,000,000 2,000,000 1,000,000 2,000,000 2,000,000 2,000,000 2,000,000 2,000,000 2,000,000 1,951,000 2,049,000 2,024,000 1,976,000                 
      impairment of long-lived assets
    		    0 0 20,000,000                         
      amortization of discounts on marketable securities
    		-3,000,000 -3,000,000 -4,000,000 -6,000,000 -6,000,000 -7,000,000 -6,000,000                         
      other items
    		   1,000,000 1,000,000   0 1,000,000 0 1,000,000                     
      changes in operating assets and liabilities:
    		                               
      receivable from collaboration partners
    		4,000,000 0 5,000,000 -4,000,000 12,000,000 7,000,000 13,000,000 0 11,000,000 -2,000,000 6,000,000 -11,809,000 7,045,000 -6,412,000 715,176,000 -17,224,000 704,000 3,660,000 -4,186,000 1,530,000 -2,357,000 122,000 -212,000         
      other assets
    		6,000,000   6,000,000 1,000,000 10,000,000 5,000,000 -2,000,000 -11,000,000 7,000,000 -8,000,000                     
      accounts payable
    		13,000,000 8,000,000 3,000,000 5,000,000 -1,000,000 0 -1,000,000 2,000,000 6,000,000 -19,000,000 10,000,000 8,054,000 -12,156,000 3,964,000 8,138,000 651,000 -1,855,000 -11,291,000 7,722,000 6,107,000 -3,503,000 9,010,000 -2,342,000 1,820,000 472,000 -49,000 -517,000 960,000 -2,376,000 1,653,000 -306,000 
      deferred revenue
    		-26,000,000 -160,000,000 -28,000,000 -42,000,000 67,000,000 -39,000,000 -42,000,000 -17,000,000 -32,000,000 6,000,000 -25,000,000 -33,655,000 -33,581,000 -26,759,000 -18,005,000 -339,501,000 -9,461,000 -9,461,000 -9,461,000 -9,511,000 191,390,000 -1,750,000 -1,750,000 -1,750,000 3,250,000 -1,750,000 -1,750,000 -1,562,000 3,709,000 -1,250,000 -1,250,000 
      other liabilities
    		24,000,000 5,000,000 -17,000,000 12,000,000 22,000,000 3,000,000 -12,000,000 -7,000,000 17,000,000 8,000,000 -21,000,000                     
      net cash from operating activities
    		-97,000,000 -133,000,000 -132,000,000 -100,000,000 26,000,000 -94,000,000 -2,000,000 -88,000,000 -63,000,000 -57,000,000 -98,000,000 -69,739,000 -80,959,000 -65,303,000 654,001,000 -62,103,000 -53,757,000 -73,995,000 -66,316,000 -49,880,000 216,265,000 -23,938,000 -31,277,000 -9,471,000 -27,399,000 -19,753,000 -16,839,000 -7,107,000 -11,765,000 -10,877,000 -13,247,000 
      capex
    		0 0 -1,000,000 -1,000,000 -1,000,000 0 -4,000,000 -6,000,000 -10,000,000 -5,000,000 -3,000,000 -380,000 -1,318,000 -1,514,000 -2,788,000 -8,506,000 -7,858,000 -6,073,000 -3,641,000 -1,519,000 -1,071,000 -256,000 -209,000 -196,000 -550,000 -551,000 -628,000 -258,000 -1,127,000 0 -359,000 
      free cash flows
    		-97,000,000 -133,000,000 -133,000,000 -101,000,000 25,000,000 -94,000,000 -6,000,000 -94,000,000 -73,000,000 -62,000,000 -101,000,000 -70,119,000 -82,277,000 -66,817,000 651,213,000 -70,609,000 -61,615,000 -80,068,000 -69,957,000 -51,399,000 215,194,000 -24,194,000 -31,486,000 -9,667,000 -27,949,000 -20,304,000 -17,467,000 -7,365,000 -12,892,000 -10,877,000 -13,606,000 
      cash flow from investing activities
    		                               
      purchases of marketable securities
    		-165,000,000 -161,000,000 -353,000,000 -172,000,000 -278,000,000 -206,000,000 -387,000,000 -115,000,000 -280,000,000 -239,000,000 -154,000,000                     
      proceeds from maturities of marketable securities
    		243,000,000 255,000,000 360,000,000 203,000,000 242,000,000 262,000,000 222,000,000 145,000,000 295,000,000 258,000,000 284,000,000                     
      proceeds from sales of marketable securities
    		1,000,000 43,000,000 26,000,000 21,000,000 8,000,000   4,000,000 6,000,000 12,000,000 2,000,000                     
      purchases of property and equipment
    		0 0 -1,000,000 -1,000,000 -1,000,000 0 -4,000,000 -6,000,000 -10,000,000 -5,000,000 -3,000,000 -380,000 -1,318,000 -1,514,000 -2,788,000 -8,506,000 -7,858,000 -6,073,000 -3,641,000 -1,519,000 -1,071,000 -256,000 -209,000 -196,000 -550,000 -551,000 -628,000 -258,000 -1,127,000   
      net cash from investing activities
    		79,000,000 137,000,000 32,000,000 51,000,000 -29,000,000 63,000,000 -169,000,000 28,000,000 11,000,000 26,000,000 129,000,000 46,811,000 23,446,000 -215,197,000 -268,060,000 18,914,000 -88,611,000 3,003,000 62,826,000 -231,000 -387,119,000 -87,073,000 40,056,000 -12,104,000 30,364,000 26,673,000 14,279,000 2,511,000 -83,337,000 -16,123,000 -16,491,000 
      cash flow from financing activities
    		                               
      proceeds from issuance of common stock
    		8,000,000 0 142,000,000  0 0 228,000,000 0         0      643,000         
      proceeds from debt issuances
    		0   0                            
      proceeds from issuance of common stock pursuant to equity award plans
    		0   3,000,000 2,000,000 3,000,000 1,000,000 3,000,000 1,000,000 3,000,000 1,000,000 6,195,000 2,531,000 4,346,000 9,928,000 6,671,000 1,318,000 2,237,000 1,885,000 1,682,000 270,000           
      payments of employee taxes related to net settlement of equity awards
    		   -5,000,000 -1,000,000                           
      net cash from financing activities
    		8,000,000 52,000,000 142,000,000 -2,000,000 48,000,000 2,000,000 229,000,000 3,000,000 6,000,000 23,000,000 1,000,000 11,195,000 2,531,000 4,346,000 14,928,000 11,671,000 1,318,000 2,231,000 222,120,000 1,677,000 107,518,000 328,870,000 610,000 520,000 -41,000 649,000 -5,000 771,000 -7,000 -1,118,000 129,428,000 
      net increase in cash, cash equivalents and restricted cash
    		-10,000,000 56,000,000 42,000,000 -51,000,000 45,000,000 -29,000,000 58,000,000 -57,000,000 -46,000,000 -8,000,000 32,000,000 -11,733,000                    
      cash, cash equivalents and restricted cash at beginning of period
    		0 0 153,000,000 0 0 0 130,000,000 0 0 0 209,000,000 81,000 0 0 150,919,000 0 0 0 173,618,000 0 0 0 58,140,000 0 0 0 71,267,000     
      cash, cash equivalents and restricted cash at end of period
    		-10,000,000 56,000,000 195,000,000 -51,000,000 45,000,000 -29,000,000 188,000,000 -57,000,000 -46,000,000 -8,000,000 241,000,000 -11,652,000 -54,982,000 -276,154,000 551,788,000 -31,518,000 -141,050,000 -68,761,000 392,248,000 -48,434,000 -63,336,000 217,859,000 67,529,000 -21,055,000 2,924,000 7,569,000 68,702,000     
      non-cash investing and financing activities:
    		                               
      unpaid portion of property and equipment purchases included in accounts payable and other current liabilities
    		      1,000,000 -4,000,000                        
      impairment on right-of use assets
    		                               
      proceeds from issuance of common stock (228, 20 and — from a related party)
    		                               
      proceeds from sale of future royalties
    		           5,000,000 0 0 5,000,000                 
      supplemental disclosure of cash flow information
    		                               
      income taxes paid
    		           257,000 0                   
      interest paid
    		                               
      amortization of premiums (discounts) on marketable securities
    		       -6,000,000 -5,000,000 -4,000,000 -4,000,000                     
      purchases of in-process research and development
    		           -500,000 0                   
      collaboration reimbursements of in-process research and development from a related party
    		           250,000                    
      unpaid portion of other assets included in accrued research and development
    		               -1,575,000                
      vesting of early exercised stock options and restricted stock
    		            0 0 52,000 157,000    205,000 207,000 216,000 220,000 245,000 251,000 260,000 273,000 294,000 335,000   
      cash flows from operating activities
    		                               
      cash flows from investing activities
    		                               
      collaboration reimbursements of in-process research and development
    		                               
      cash flows from financing activities
    		                               
      proceeds from issuance of common stock to a related party
    		                               
      unpaid portion of property and equipment purchases included in accounts payable and accrued liabilities
    		         4,000,000 4,000,000 1,665,000 718,000 -74,000 691,000 -3,609,000 -1,883,000 3,704,000 2,784,000 1,338,000 135,000 34,000 76,000 -21,000 -15,000 -332,000 380,000 33,000 -904,000   
      unpaid acquisition of in-process research and development
    		              2,500,000                 
      amortization of premiums on marketable securities
    		                               
      proceeds from issuance of common stock and rights to purchase additional shares
    		                               
      amortization of premiums on investments
    		            -368,000 710,000 1,670,000 1,968,000 1,392,000 906,000 506,000 287,000 -10,000 -75,000 -248,000 -425,000 -633,000 -833,000 -747,000     
      acquired in-process research and development
    		            -1,250,000 0 2,500,000                 
      effective interest on liability for sale of future royalties
    		            535,000 511,000 391,000                 
      prepaid expenses and other current assets
    		            -6,180,000 9,618,000 -5,590,000 -654,000 3,796,000 -4,518,000 -4,568,000 7,047,000 -3,284,000 -897,000 -3,704,000 -80,000 -950,000 -193,000 -759,000 8,000 -779,000 284,000 -693,000 
      other long-term assets
    		            -194,000 285,000 -1,727,000 2,572,000 279,000 408,000 63,000 -4,001,000 -1,238,000 -44,000 -91,000 -609,000 56,000 -5,000 -30,000     
      accrued research and development
    		            4,808,000 2,865,000 5,567,000 -10,808,000                
      other accrued liabilities
    		            6,090,000 -1,758,000 -8,462,000 5,056,000 4,919,000 2,170,000 -2,007,000             
      operating lease liabilities
    		            -1,727,000 -1,276,000 92,000 117,000 -402,000 -398,000 -605,000             
      other long-term liabilities
    		            1,069,000 375,000 2,270,000 -496,000 0 0 -2,000 2,228,000 7,663,000           
      purchases of short-term and long-term investments
    		            -322,261,000 -385,558,000 -377,573,000 -134,015,000 -214,160,000 -178,292,000 -192,398,000 -170,755,000 -429,214,000 -130,804,000 -8,885,000 -67,510,000 -56,408,000 -51,430,000 -72,407,000 -39,485,000 -131,396,000   
      proceeds from maturities of short-term and long-term investments
    		            228,036,000 169,007,000 93,817,000 117,934,000 133,407,000 187,368,000 251,365,000 172,043,000 43,166,000 42,984,000 49,150,000 55,602,000 87,322,000 78,654,000 87,314,000 42,254,000    
      sales of short-term and long-term investments
    		            116,239,000 8,368,000 18,484,000 43,501,000 0 0 7,500,000             
      repurchase of unvested shares of stock
    		               0 0   -5,000 -16,000 0 -33,000  -43,000 -46,000 -5,000     
      net increase in cash and cash equivalents
    		             -276,154,000 400,869,000  -141,050,000 -68,761,000 218,630,000  -63,336,000 217,859,000 9,389,000         
      share of income from equity method investee
    		                    0 131,000 482,000 0 358,000 413,000 431,000 323,000 186,000 151,000 226,000 
      amounts owed by pact pharma
    		                               
      other current liabilities
    		                       15,000 13,000 15,000 14,000 10,000 13,000 11,000 9,000 
      deferred rent
    		                    1,007,000 -137,000 -129,000 -141,000 -135,000 -135,000 -127,000 -124,000 -120,000 -139,000 -85,000 
      unpaid portion of financing costs included in accounts payable
    		                               
      amortization of right-of-use assets
    		                584,000 579,000 538,000             
      supplemental disclosures:
    		                               
      cash paid for amounts included in measurement of lease liabilities
    		                1,074,000 1,073,000 927,000             
      cash received from tenant improvement allowances
    		                               
      right-of-use assets obtained in exchange for new operating lease liabilities
    		                0               
      recognition of tenant improvement allowance receivable included in other current assets
    		                               
      unpaid portion of financing costs included in accrued liabilities
    		                               
      accrued research and development expenses
    		                 5,733,000 4,716,000 -9,930,000 14,338,000           
      tenant improvement allowance receivable included in other current assets
    		                               
      vesting of early exercised stock options
    		                 175,000 183,000             
      unpaid portion of deferred financing costs included in accounts payable
    		                               
      proceeds from issuance of common stock to related party
    		                  220,235,000             
      share of loss (gain on deemed sale) from equity method investee
    		                               
      other non-operating income
    		                           0 0 -118,000 -59,000 
      sales of short-term investments
    		                   0 0           
      proceeds from initial public offering, net of issuance costs
    		                           0 -3,000 -1,145,000 126,259,000 
      payment of preferred stock issuance costs
    		                           0 0 0 -135,000 
      gain on deemed sale from equity method investee
    		                    0 -131,000 -482,000     0 0   
      amounts owed by a related party
    		                       0 62,000 -62,000 83,000 31,000 79,000 -139,000 -29,000 
      accrued liabilities
    		                    1,824,000 13,000 648,000 -140,000 -5,890,000 7,923,000 1,606,000 -644,000 2,329,000 1,402,000 410,000 
      proceeds from issuance of common stock and rights to purchase additional shares, net of issuance costs
    		                               
      proceeds from issuance of common stock, net of issuance costs
    		                               
      receivable from collaboration partner
    		                               
      repurchase of common stock issued under early exercised options
    		                               
      net decrease in cash, cash equivalents and restricted cash
    		                               
      proceeds from issuance of common stock upon exercise of stock options, net of repurchases
    		                        2,000   771,000 -4,000 27,000 3,304,000 
      net decrease (increase) in cash and cash equivalents
    		                         7,569,000 -2,565,000     
      changes in operating assets and liabilities
    		                               
      unpaid financing cost included in accounts payable and accrued liabilities
    		                              1,170,000 
      (accretion of discounts) amortization of premiums on investments
    		                               
      investment in related party
    		                               
      proceeds from issuance of preferred stock, net of issuance costs
    		                               
      deferred initial public offering costs
    		                               
      net decrease in cash and cash equivalents
    		                           -3,825,000 -95,109,000 -28,118,000 99,690,000 
      cash and cash equivalents at beginning of period
    		                           0 0 0 98,426,000 
      cash and cash equivalents at end of period
    		                           -3,825,000 -95,109,000 -28,118,000 198,116,000 
      accretion of discounts (amortization of premiums) on investments
    		                               
      proceeds from maturities of short-term investments
    		                             34,768,000 25,647,000 
      adjustments to reconcile net earnings to net cash from operating activities:
    		                               
      purchase of short-term and long-term investments
    		                              -41,084,000 
      purchase of property and equipment
    		                              -1,054,000 
      purchase of property and equipment purchases included in accounts payable and accrued liabilities
    		                              695,000 
      vesting of early exercised options and restricted stock
    		                              278,000 
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.